{"entity":{"id":"immunext","kind":"company","name":"ImmuNext","aka":["ImmuNext Inc"],"tldr":"ImmuNext is a small US company that makes antibodies to adjust the immune system. In cancer its main work was an antibody against VISTA, a brake on immune cells, which it licensed first to Janssen and later offered to Curis.","summary":"ImmuNext, of Lebanon, New Hampshire, describes itself as developing compounds for immunotherapy of cancer and autoimmune disease. Its lead oncology asset is an anti-VISTA antibody: CI-8993, formerly JNJ-61610588, a clinical-stage monoclonal antibody that antagonises VISTA signalling, originally partnered with Janssen for cancer. In January 2020 Curis paid an upfront fee for an option to an exclusive worldwide licence to ImmuNext's anti-VISTA antagonist antibodies in oncology, with development, regulatory and commercial milestones and royalties, and planned a Phase 1a/1b study of CI-8993. Outside cancer, ImmuNext licensed INX-021, a CD40L antibody then in preclinical development, to Sanofi in January 2017 with potential milestone payments of up to USD 500 million, and partnered VISTA agonists with Roche for autoimmune disease. The 2017 release also named a CD40 agonist for neoantigen cancer vaccines.","asOf":"2026-11-03","links":[{"label":"Official website","url":"https://www.immunext.com/"},{"label":"Curis and ImmuNext option and licence agreement, January 2020 (SEC 8-K exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1108205/000119312520002601/d863849dex991.htm"},{"label":"Sanofi and ImmuNext agreement, January 2017 (PR Newswire reprint)","url":"https://www.inknowvation.com/sbir/story/sanofi-and-immunext-enter-agreement-develop-treatments-autoimmune-diseases?keywords="}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["checkpoint-inhibitor"],"targets":["vista"],"drugs":[],"companies":["curis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company website shows only a contact address, so these facts come from the Curis release filed with the SEC and the 2017 Sanofi release as reprinted by a third party. Founding year, funding and current stage are not stated in any source read, so they are left out. Whether Curis exercised its option, and what became of CI-8993, was not checked. Linking INX-021 to Sanofi's frexalimab rests on a secondary database and is not asserted here."],"hq":"Lebanon, NH","country":"US","companyType":"biotech","website":"https://www.immunext.com/","investors":[],"funding":[]},"route":"/companies/immunext/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"vista","kind":"target","name":"VISTA","route":"/targets/vista/"}],"company":[{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/"}]}}